Evaluation of renal end points in nephrology trials

Misghina Tekeste Weldegiorgis

    Research output: ThesisThesis fully internal (DIV)

    861 Downloads (Pure)


    Chronic kidney disease (CKD) is a public health problem and is associated with a high risk of dialysis, renal transplantation, and cardiovascular disease. To date, very few interventions have been proven to be effective for slowing the progression of kidney function decline. Novel therapeutic strategies are thus desired to address the high unmet medical need of CKD.
    Clinical outcome trials are required to ultimately establish a drug’s efficacy and safety. The current established trial end points in CKD are late events in the progression of CKD which lead to large and complex trials to ultimately assess the efficacy of new interventions for slowing the progression of CKD. This thesis has explored new definitions for clinical trial end points in CKD.
    The findings described in this thesis indicate that the optimal end point in clinical trials of CKD progression should be a composite end point consisting of a decline in kidney function together with a clinically meaningful end point such as dialysis or kidney transplantation. With respect to the decline in renal function, this thesis helped to establish a new end point namely a 30% and 40% estimated glomerular filtration rate (eGFR) decline which is currently used in new clinical trials of CKD progression.
    Translated title of the contributionEvaluatie van renale eindpunten in nefrologische klinische studies
    Original languageEnglish
    QualificationDoctor of Philosophy
    Awarding Institution
    • University of Groningen
    • Lambers Heerspink, Hiddo, Supervisor
    • de Zeeuw, Dick, Supervisor
    Award date8-Nov-2017
    Place of Publication[Groningen]
    Print ISBNs978-94-034-0154-6
    Electronic ISBNs978-94-034-0153-9
    Publication statusPublished - 2017

    Cite this